Vijaya Diagnostic Centre / Q3-FY26

Read the quarter in context.

A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

Positive2026-01-15Back to VIJAYADIAGNOSTICCENTRE

Revenue

₹205 Cr

verified against source

Revenue YoY

21.4%

reported change

EBITDA

₹86 Cr

latest reported figure

Source

screener in

record provenance

Actual signal trajectory

Where this quarter sits.

source records only
EBITDA (₹ Cr)PositiveWatchNegative
2 actual records
Actual quarterly EBITDA (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q3 FY26: 86 · Positive source sentiment · 2026-01-15Q3 FY26Q4 FY26: 95.5 · Positive source sentiment · 2026-05-15Q4 FY2695.586
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Quarter read

What the record says.

Vijaya Diagnostic delivered a record quarter with revenue of ₹205 crore (+21.4% YoY) and EBITDA margin expansion of 221 bps to 41.9%, driven by strong volume growth of 14.7% and favorable seasonality. The core Hyderabad market grew 15% organically, while new hubs in West Bengal and Bangalore broke even ahead of schedule. Management guided for 4-5 new hubs and 10-12 spokes in FY27, with capex of ₹100-120 crore. EBITDA margin guidance remains at ~40% due to investments in talent and digital initiatives. Key risk: competitive intensity from organized chains entering radiology could pressure pricing in new geographies.

Colored figures show movement against the previous available record.

Guidance to track

  • Capex outlay for new hubs and spokes in FY27 estimated at ₹100-120 crore, inclusive of replacement capex.
  • Management plans to add 4-5 hubs and 10-12 spokes in FY27, with more spokes in FY28-29.
  • Despite operating leverage from faster break-even, management guides EBITDA margin at ~40% due to investments in talent and digital.
  • Management maintains guidance that new hubs outside Hyderabad will break even within 12-14 months, though recent hubs achieved it in 3 quarters.

Risks flagged

  • Large pathology chains are venturing into advanced radiology, potentially increasing competition in core and new markets.
  • As new hubs stabilize, higher pathology share could reduce revenue per test, though tariff hikes may offset.
  • USD/INR volatility and GST changes could affect equipment costs, though management expects minimal net impact.
  • Rapid hub and spoke expansion in West Bengal, Bangalore, and Pune may strain operational bandwidth and delay stabilization.

Key quotes

  • I think both consolidation and disruption they'll take its own time and like you rightly said these players... they're at a very initial stage where they're doing a pilot in their home geographies.
  • The differential would be... the work that comes in is just not wellness-driven. So it's a lot more that's also reason why you see the PET cities ramping up quickly.
  • We still want to guide the margins at 40%. The reason being we are also doing significant investments onto talent and onto few IT initiatives.

Research modules

Go one layer deeper.